Dietary Supplement
Oligo Fucoidan
Oligo Fucoidan is a dietary supplement with 3 clinical trials. Historical success rate of 50.0%.
Total Trials
3
Max Phase
—
Type
DIETARY SUPPLEMENT
Molecule
—
Success Metrics
Clinical Success Rate
50.0%
Based on 1 completed trials
Completion Rate
50%(1/2)
Active Trials
0(0%)
Results Posted
0%(0 trials)
Terminated
1(33%)
Phase Distribution
Ph early_phase_1
1
33%
Ph not_applicable
2
67%
Phase Distribution
1
Early Stage
0
Mid Stage
0
Late Stage
Phase Distribution3 total trials
Early Phase 1First-in-human
1(33.3%)
N/ANon-phased studies
2(66.7%)
Highest Phase Reached
Early Phase 1Trial Status & Enrollment
Completion Rate
33.3%
1 of 3 finished
Non-Completion Rate
66.7%
2 ended early
Currently Active
0
trials recruiting
Total Trials
3
all time
Status Distribution
Completed(1)
Terminated(2)
Detailed Status
Withdrawn1
Completed1
Terminated1
Development Timeline
Analytics
Development Status
Total Trials
3
Active
0
Success Rate
50.0%
Most Advanced
Early Phase 1
Trials by Phase
Early Phase 11 (33.3%)
N/A2 (66.7%)
Trials by Status
withdrawn133%
completed133%
terminated133%
Recent Activity
0 active trials
Showing 3 of 3
completedearly_phase_1
Effects of Oligo-fucoidan on Leiomyoma Patients
NCT06959966
terminatednot_applicable
Study of Oligo-Fucoidan in Advanced Hepatocellular Carcinoma (HCC)
NCT04066660
withdrawnnot_applicable
To Evaluate the QoL Improvement of Oral Oligo Fucoidan in Subjects Receiving Platinum-based Chemotherapy With NSCLC
NCT03130829
Clinical Trials (3)
Showing 3 of 3 trials
NCT06959966Early Phase 1
Effects of Oligo-fucoidan on Leiomyoma Patients
NCT04066660Not Applicable
Study of Oligo-Fucoidan in Advanced Hepatocellular Carcinoma (HCC)
NCT03130829Not Applicable
To Evaluate the QoL Improvement of Oral Oligo Fucoidan in Subjects Receiving Platinum-based Chemotherapy With NSCLC
All 3 trials loaded
Drug Details
- Intervention Type
- DIETARY SUPPLEMENT
- Total Trials
- 3